Merck's ESMO 2026 Triple Readout: First-in-Class Vaccine, ADC, and dMMR Checkpoint Data Test the Limits of Pembrolizumab's Franchise Extension

Merck Unveils Pivotal Phase 3 Oncology Data at ESMO 2026

Merck announced that it will present first-time pivotal Phase 3 results from three key oncology trials at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, from October 23-27. These presentations include data for intismeran autogene in combination with KEYTRUDA for resected melanoma, sacituzumab tirumotecan for advanced or recurrent endometrial cancer, and KEYTRUDA monotherapy for dMMR advanced or recurrent endometrial cancer. The company will also showcase over 90 additional abstracts across more than 20 tumor types, reinforcing the breadth of its oncology pipeline and portfolio.

• The pivotal Phase 3 INTerpath-001 trial, evaluating intismeran autogene, a novel mRNA-based individualized neoantigen therapy developed in collaboration with Moderna, in combination with KEYTRUDA, demonstrated improvements in recurrence-free survival and distant metastasis-free survival. This data, presented in a Presidential Symposium, focuses on its use as adjuvant treatment for patients with completely resected stage IIB-IV melanoma.
• First-time data from the pivotal Phase 3 TroFuse-005 trial will be presented for sacituzumab tirumotecan, an investigational TROP2-directed antibody-drug conjugate developed with Kelun-Biotech. This trial showed improvements in overall survival and progression-free survival in patients with advanced or recurrent endometrial cancer who had progressed after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor.
• Results from the Phase 3 KEYNOTE-C93 trial will highlight the important role of KEYTRUDA monotherapy as a first-line treatment for patients with mismatch repair deficient (dMMR) advanced or recurrent endometrial cancer. This study included patients who had not previously received systemic chemotherapy or experienced recurrence after prior adjuvant therapy, further expanding KEYTRUDA's potential in this setting.

Pivotal INTerpath-001 Data: Intismeran Autogene in Adjuvant Melanoma

The OPTiM trial, a randomized open-label phase III study, evaluated talimogene laherparepvec against subcutaneous recombinant GM-CSF in 436 patients with unresectable stage IIIB–IVM1c melanoma. In the final planned analysis, with a median follow-up of 49 months, median overall survival was 23.3 months (95% CI, 19.5–29.6) in the talimogene laherparepvec arm versus 18.9 months (95% CI, 16.0–23.7) in the GM-CSF arm (unstratified hazard ratio, 0.79; 95% CI, 0.62–1.00; p = 0.0494 [descriptive]). The durable response rate was 19.0% versus 1.4%, the objective response rate was 31.5% versus 6.4%, and complete responses were achieved in 16.9% versus 0.7% of patients, respectively. Median time to complete response was 8.6 months, and among patients achieving a complete response, 88.5% were estimated to survive at a 5-year landmark analysis. The safety profile was consistent with the primary analysis.

A phase 2 study of glembatumumab vedotin — an antibody-drug conjugate targeting glycoprotein NMB — enrolled 62 patients with stage IV melanoma refractory to checkpoint inhibition and BRAF/MEK inhibition. The objective response rate was 11%, with a median response duration of 6.0 months (95% CI, 4.1 months to not reached). Median progression-free survival was 4.4 months (95% CI, 2.6–5.5 months) and median overall survival was 9.0 months (95% CI, 6.1–11.7 months). Patients who developed rash during the first cycle demonstrated an ORR of 21% versus 7% in those who did not, along with improved PFS (hazard ratio, 0.43; p = .013) and OS (hazard ratio, 0.43; p = .017). The most frequent adverse events were alopecia, neuropathy, rash, fatigue, and neutropenia. Seventy-six percent of evaluable tumors had 100% gpNMB-positive epithelial cells.

A study of neoadjuvant checkpoint inhibitor immunotherapy — predominantly combination nivolumab and ipilimumab (administered in 78% of patients) — in 36 patients with resectable mucosal melanoma reported an objective response rate of 47% and a pathologic response rate of 35%. With a median follow-up of 37.9 months, median event-free survival was 9.2 months with a 3-year event-free survival rate of 29%; median overall survival had not been reached, with a 3-year overall survival rate of 55%. Event-free survival and overall survival were significantly higher for patients achieving objective or pathologic response. Grade 3 toxicities were reported in 39% of patients.

Addressing Unmet Needs in Resected Stage IIB-IV Melanoma

Despite meaningful advances in immunotherapy and targeted therapy, melanoma treatment continues to face substantial clinical obstacles rooted in resistance, toxicity, and disease heterogeneity. These challenges span both BRAF-targeted and immune checkpoint inhibitor (ICI) approaches, and are particularly pronounced in high-risk and metastatic settings.

• Acquired resistance to BRAF/MEK inhibition is near-universal. Mitogen-activated protein kinase (MAPK) reactivation mechanisms were detected in 70% of disease-progressive tissues following BRAF inhibitor therapy, with RAS mutations, mutant BRAF amplification, and alternative splicing being most common. PI3K-PTEN-AKT-upregulating genetic alterations were identified in an additional 22% of progressive melanomas, and distinct molecular lesions in both core drug escape pathways were commonly detected concurrently within the same tumor or across multiple tumors from the same patient.

• Sequencing BRAF-MEK inhibition after PD-1-based therapy carries significant tolerability challenges. Among 78 patients who received combined BRAF and MEK inhibition following prior PD-1-based therapy, 83% of regimens required at least one dose modification, with a median time to first dose modification of 14 days. Pyrexia accounted for 71% of dose modifications, and 31% of modifications led to an adverse event-related hospitalization. Dose modifications were more common in patients receiving BRAF-MEK therapy fewer than 90 days after the last dose of PD-1 therapy and who were not receiving steroids. Among 55 BRAF-naive patients in this post-PD-1 setting, the median time receiving BRAF-MEK therapy was 5.8 months and median overall survival was 15.6 months, outcomes potentially inferior to those reported in published Phase 3 trials.

• Acquired resistance to PD-1 blockade involves complex immune escape mechanisms. In patients with metastatic melanoma who achieved initial objective tumor regression with pembrolizumab but subsequently progressed, whole-exome sequencing identified loss-of-function mutations in JAK1 or JAK2 in two of four patients, concurrent with deletion of the wild-type allele, resulting in insensitivity to interferon gamma's antiproliferative effects. A truncating mutation in B2M was identified in a third patient, leading to loss of surface expression of major histocompatibility complex class I. Approximately 75% of objective responses to anti-PD-1 therapy are durable, but delayed relapses have been observed long after initial tumor regression.

• Recurrence following adjuvant ICI therapy remains a significant unmet need in stage III disease. Despite adjuvant immune checkpoint inhibitor therapy significantly reducing recurrence rates compared with surgery alone, 48% of anti-PD-1-treated patients with stage III melanoma develop recurrent disease within 4 years, underscoring the need for predictive biomarkers to identify patients requiring alternative treatment strategies.

• Melanoma brain metastases present distinct therapeutic barriers. The proportion of patients with cutaneous melanoma diagnosed with brain metastases at presentation was 33% (975 of 2,948 patients) in a systematic literature review, with male sex and left-sided primary tumors significantly associated with increased risk. While stereotactic radiosurgery and ICI combinations show promise, blood-brain barrier permeability limits the delivery of therapeutic antibodies, and CD73/adenosine axis-mediated immune evasion further constrains ICI efficacy in the intracranial compartment.

• Rare but severe immune-related adverse events complicate ICI use. ICI-induced gastrointestinal dysautonomia, though rare, carries a mortality rate of 47.0% (8 of 17 patients with known outcomes) based on a systematic review of 18 individual cases. Onset occurred at a mean of 13.6 weeks (SD 14.3) from ICI exposure, and corticosteroids — the primary treatment in 72% of cases — were used at limited duration and low dose in 46.2% of those treated, with gastrointestinal recovery achieved in only 38.5% of patients.

Exploring Neoantigen Therapy: A Novel Approach in Melanoma

Research into novel therapeutic targets for melanoma has expanded considerably beyond the foundational BRAF/MEK inhibitor paradigm. For NRAS-mutant melanoma — affecting an estimated 75,000 patients annually — combined inhibition of MEK1/2 and CDK4/6 has emerged as a central investigational strategy, with clinical cases demonstrating response to binimetinib and ribociclib in tumors harboring homozygous CDKN2A deletion alongside NRAS mutation. Resistance to this combination has been mapped through functional genetic screens, revealing that upregulation of the RTK-RAS-RAF and RTK-PI3K-AKT signaling cascades are primary escape mechanisms. A preexisting rare PIK3CA mutation has been identified as conferring clinical resistance to MEK plus CDK4/6 inhibition, with activated S6K1 identified as both a key resistance marker and a specific therapeutic vulnerability downstream of PIK3CA. In BRAF/MEK inhibitor-refractory disease, acquired oncogenic NRAS mutations and loss of CDKN2A have been identified as drivers of resistance, and the combination of trametinib and palbociclib has demonstrated significant tumor growth reduction in patient-derived xenograft models, with CDKN2A loss proposed as a biomarker of response. MDM2 antagonism represents a further mechanistic avenue: coadministration of CDK4/6 and MDM2 antagonists stabilizes p53, induces p21 accumulation, and has produced tumor regression in preclinical melanoma models, including in combination with standard-of-care therapy.

In the immune checkpoint space, the approval of relatlimab (anti-LAG-3) in combination with nivolumab for first-line metastatic melanoma has established LAG-3 as the third clinically validated immune checkpoint, following PD-1 and CTLA-4. The RELATIVITY-047 trial validated LAG-3 blockade as a relevant biological target, with the combination offering meaningful efficacy and modest increases in toxicity relative to single-agent PD-1 inhibition. Beyond LAG-3, multiple additional checkpoint molecules are under active investigation, including TIM-3, TIGIT, VISTA, IDO1/IDO2/TDO, CD27/CD70, CD39/73, HVEM/BTLA/CD160, and B7-H3, each representing co-inhibitory or co-stimulatory axes with distinct immunomodulatory properties. Emerging combination strategies layer these novel checkpoints with chemotherapy, radiation, targeted agents, and adoptive cell transfer to address multiple immune evasion mechanisms simultaneously. T-cell exhaustion within the tumor microenvironment — driven by immunosuppressive factors from myeloid-derived suppressor cells, tumor-associated macrophages, and cancer-associated fibroblasts — is increasingly recognized as a therapeutic target, with checkpoint inhibitor blockade targeting PD-1, TIM-3, and CTLA-4, alone or in combination with cytokine co-stimulation, being evaluated to re-invigorate exhausted T cells.

For uveal melanoma (UM), where GNAQ and GNA11 mutations are present in approximately 90% of tumors and no effective systemic therapy exists for metastatic disease, several distinct targets are under investigation. Phosphoproteomic analyses have identified that oncogenic Gq/11 signaling drives PKC, ERK, CDK1, CDK2, mTORC1, and 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 activity, each representing a candidate therapeutic node. mTOR inhibition with everolimus has reduced viability in UM cell lines and significantly delayed tumor growth in patient-derived xenograft models. ERK inhibition with ulixertinib (BVD-523) was evaluated in a Phase II study of 13 metastatic UM patients; the best response was stable disease in 4 patients, with a median time to progression of 2.0 months and median overall survival of 6.9 months, leading to the conclusion that BVD-523 did not demonstrate activity in this setting. Novel targets such as IMCgp100 and glembatumumab have shown activity in early studies. Epigenetic regulation of UM development is also under consideration as a potential therapeutic target, alongside new drugs designed to inhibit the protein products of mutant genes or stimulate immune responses against specific antigens.

Pivotal Data to Reshape Melanoma and Endometrial Cancer Care

The upcoming ESMO 2026 congress is set to be a landmark event for Merck, with pivotal Phase 3 data presentations that could significantly reshape treatment strategies in melanoma and endometrial cancer. The highly anticipated results for intismeran autogene in combination with KEYTRUDA for resected melanoma represent a potential breakthrough in individualized neoantigen therapy. Building on earlier Phase 2b findings that demonstrated improved recurrence-free survival, these Phase 3 data could validate the mRNA platform as a powerful tool in oncology, offering a new adjuvant option for high-risk patients. However, as with any novel combination, careful consideration of potential immune-related adverse events, which can be severe, will be paramount in clinical practice.

In endometrial cancer, Merck is poised to present data for two distinct yet impactful therapies. First, sacituzumab tirumotecan, a TROP2-directed antibody-drug conjugate, has shown promising activity and a manageable safety profile in other difficult-to-treat cancers like NSCLC and triple-negative breast cancer. Its potential efficacy in advanced or recurrent endometrial cancer could introduce a vital new targeted therapy, addressing a significant unmet need. Clinicians will need to be prepared to manage common ADC-related toxicities, such as hematologic events and stomatitis, which have been observed in prior studies.

Second, KEYTRUDA monotherapy for dMMR advanced or recurrent endometrial cancer will further solidify the role of immune checkpoint inhibitors in this biomarker-selected population. Previous studies, notably KEYNOTE-158, have already established pembrolizumab's durable responses and high objective response rates in dMMR solid tumors, including endometrial cancer. These Phase 3 results are expected to reinforce its position, potentially expanding its use or moving it into earlier treatment lines. Despite its proven benefits, the risk of serious immune-related adverse events, including rare but life-threatening conditions like diabetic ketoacidosis, necessitates ongoing patient monitoring and proactive management. Collectively, these presentations underscore Merck's commitment to advancing precision medicine and immunotherapy across a broad oncology portfolio.